地中海贫血市场规模、份额和趋势分析报告：按治疗方法、类型、地区和细分市场预测，2024-2030 年

地中海贫血市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球地中海贫血市场规模预计将达到14.301亿美元，2024年至2030年复合年增长率为7.8%。

对通用治疗方法的需求增加、对该疾病的认识提高以及技术进步可能会增加基因疗法的采用。

地中海贫血是一组遗传性血液疾病，身体产生异常血红蛋白，导致红血球遭到破坏。这最终会导致贫血。地中海贫血主要有两种：α地中海贫血和β地中海贫血，后者更严重。 β地中海型贫血是一种体染色体隐性遗传疾病，在美国相对罕见。

地中海贫血盛行率的增加预计将推动市场成长。儘管技术不断进步，但对可靠治疗方案的需求仍未被满足。地中海贫血的治疗主要限于定期输血和铁螯合疗法。大多数治疗地中海贫血的药物可以治疗贫血、铁超载和维生素缺乏等症状和副作用。然而，基因疗法正成为这种疾病的可靠治疗方法。

据报道，地中海贫血的盛行率多年来在各个地区逐渐增加。这可能是因为人口迁移、婚姻以及遗传和环境因素驱动了该疾病及其影响。

地中海贫血市场报告亮点

• 铁螯合药物细分市场在 2023 年占据最大收益占有率，达到 52.7%。地中海贫血患者经常需要定期输血，这会导致体内铁超载。
• β-地中海型贫血占2023年最大销售份额，为71.2%。 β-地中海贫血诊断技术和治疗方案的不断进步显着改善了患者的预后。
• 北美地中海贫血市场主导全球市场，2023年销售份额为42.8%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章地中海贫血市场变数、趋势与范围

• 市场介绍/系统展望
• 市场规模及成长前景
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 地中海型贫血市场分析工具
  • 波特的分析
  • PESTEL分析

第四章地中海贫血市场：治疗评估与趋势分析

• 细分仪表板
• 地中海型贫血市场：2023 年和 2030 年治疗变化分析
• 铁螯合药物
• 红色甲状腺成熟者
• 干细胞疗法
• 其他的

第五章地中海贫血市场：类型估计和趋势分析

• 细分仪表板
• 地中海贫血市场：2023 年和 2030 年按类型变化分析
• α地中海贫血
• β地中海型贫血

第六章地中海贫血市场：区域估计与趋势分析

• 2023 年及 2030 年地中海贫血市场占有率（按地区）
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 英国。
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 丹麦
  • 瑞典
  • 挪威
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 泰国
• 拉丁美洲
  • 巴西
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 科威特

第七章 竞争格局

• 主要市场参与企业的最新趋势和影响分析
• 公司分类
• 企业热力图分析
• 公司简介
  • CHIESI Farmaceutici SpA
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Cipla
  • Fresenius Kabi AG
  • Novartis Pharmaceuticals Corporation
  • Apotex Inc.
  • bluebird bio, Inc.

Thalassemia Market Growth & Trends:

The global thalassemia market size is expected to be valued at USD 1,430.1 million by 2030, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 7.8% from 2024 to 2030. Increase in demand for a universal cure, rise in awareness about the disease, and technological advancements are likely to increase the adoption of gene therapies.

Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in the destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in the U.S.

Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.

Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.

Thalassemia Market Report Highlights:

• The iron chelating drugs segment held the largest revenue share of 52.7% in 2023. Patients with thalassemia often require regular blood transfusions, which can lead to iron overload in the body.
• The beta thalassemia held the largest revenue share of 71.2% in 2023. Ongoing advancements in diagnostic techniques and treatment options for beta thalassemia have significantly improved patient outcomes.
• North America thalassemia market dominated the global market with a revenue share of 42.8% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Thalassemia Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Thalassemia Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Thalassemia Market: Treatment Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Thalassemia Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Iron Chelating Drugs
  • 4.3.1. Iron Chelating Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Erythyroid Maturation Agents
  • 4.4.1. Erythyroid Maturation Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Stem Cell therapy
  • 4.5.1. Stem Cell Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Thalassemia Market: Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Thalassemia Market: Type Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Alpha Thalassemia
  • 5.3.1. Alpha Thalassemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Beta Thalassemia
  • 5.4.1. Beta Thalassemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Thalassemia Market: Regional Estimates & Trend Analysis

• 6.1. Thalassemia Market Share, By Region, 2023 & 2030 (USD Million)
• 6.2. North America
  • 6.2.1. North America Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. U.S. Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.3. Canada
    • 6.2.3.1. Canada Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.4. Mexico
    • 6.2.4.1. Mexico Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.3. Europe
  • 6.3.1. Europe Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. UK.
    • 6.3.2.1. UK Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Germany
    • 6.3.3.1. Germany Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.4. France
    • 6.3.4.1. France Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.5. Italy
    • 6.3.5.1. Italy Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.6. Spain
    • 6.3.6.1. Spain Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.7. Denmark
    • 6.3.7.1. Denmark Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.8. Sweden
    • 6.3.8.1. Sweden Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.9. Norway
    • 6.3.9.1. Norway Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Japan Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. China
    • 6.4.3.1. China Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. India
    • 6.4.4.1. India Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. Australia
    • 6.4.5.1. Australia Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. South Korea
    • 6.4.6.1. South Korea Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.7. Thailand
    • 6.4.7.1. Thailand Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. Latin America Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Brazil Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Argentina
    • 6.5.3.1. Argentina Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Middle East and Africa
  • 6.6.1. Middle East and Africa Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. UAE
    • 6.6.4.1. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Kuwait
    • 6.6.5.1. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. CHIESI Farmaceutici S.p.A.
    • 7.4.1.1. Participant's Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Recent Developments/ Strategic Initiatives
  • 7.4.2. Bristol-Myers Squibb Company
    • 7.4.2.1. Participant's Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Recent Developments/ Strategic Initiatives
  • 7.4.3. Sun Pharmaceutical Industries Ltd.
    • 7.4.3.1. Participant's Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Recent Developments/ Strategic Initiatives
  • 7.4.4. Cipla
    • 7.4.4.1. Participant's Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Recent Developments/ Strategic Initiatives
  • 7.4.5. Fresenius Kabi AG
    • 7.4.5.1. Participant's Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Recent Developments/ Strategic Initiatives
  • 7.4.6. Novartis Pharmaceuticals Corporation
    • 7.4.6.1. Participant's Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Recent Developments/ Strategic Initiatives
  • 7.4.7. Apotex Inc.
    • 7.4.7.1. Participant's Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Recent Developments/ Strategic Initiatives
  • 7.4.8. bluebird bio, Inc.
    • 7.4.8.1. Participant's Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Recent Developments/ Strategic Initiatives